Tag Archives: Keay Nakae

Chardan Capital Thinks Ocugen’s Stock is Going to Recover

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Ocugen (OCGN – Research Report) yesterday and set a price target of $2.00. The company’s shares closed last Friday at $0.30, close to its 52-week low of $0.24. According to

Chardan Capital Reiterates a Buy Rating on Caladrius Biosciences (CLBS)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Caladrius Biosciences (CLBS – Research Report), with a price target of $6.00. The company’s shares closed last Thursday at $1.70. According to TipRanks.com, Nakae is

Arbutus Biopharma (ABUS) Gets a Buy Rating from Chardan Capital

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report), with a price target of $5.00. The company’s shares closed last Tuesday at $1.65. According to TipRanks.com, Nakae is

Chardan Capital Reiterates a Buy Rating on OncoCyte (OCX)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on OncoCyte (OCX – Research Report) today and set a price target of $7.75. The company’s shares closed last Tuesday at $2.70. According to TipRanks.com, Nakae is a 4-star analyst with

Analysts Offer Insights on Healthcare Companies: Lineage Cell Therapeutics (NYSE MKT: LCTX), Intercept Pharma (NASDAQ: ICPT) and BioDelivery (NASDAQ: BDSI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Cell Therapeutics (LCTX – Research Report), Intercept Pharma (ICPT – Research Report) and BioDelivery (BDSI – Research Report) with bullish sentiments.

Chardan Capital Reaffirms Their Buy Rating on Dicerna Pharma (DRNA)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Dicerna Pharma (DRNA – Research Report), with a price target of $25.00. The company’s shares closed last Thursday at $22.85. According to TipRanks.com, Nakae is